Nanogen - Gute News - 500 Beiträge pro Seite
eröffnet am 27.10.00 10:20:51 von
neuester Beitrag 31.10.00 15:01:14 von
neuester Beitrag 31.10.00 15:01:14 von
Beiträge: 12
ID: 282.942
ID: 282.942
Aufrufe heute: 0
Gesamt: 780
Gesamt: 780
Aktive User: 0
ISIN: US6300751095 · WKN: 911841
Werte aus der Branche Nanotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3700 | +19,13 | |
| 2,1550 | +5,38 | |
| 189,77 | +4,08 | |
| 35,16 | +2,21 | |
| 1,4800 | +2,07 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,8700 | -0,41 | |
| 1,1000 | -0,90 | |
| 1,3102 | -1,27 | |
| 31,30 | -1,57 | |
| 0,7838 | -3,62 |
Feedback!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
KAAAAAAAAAAAAAUUUUUUUUUUUUUUUUFFFFFFFFFFFFFFFEEEEEEEEEENNNNNNNNNNNN !!!!!!!!
Das könnte endlich der Tropfen sein, der das Fass zum
Überlaufen bringt.
Nanotechnologie kristallisiert sich immer mehr als der nächste
Trend nach/mit Biotechnologie heraus. Bin gespannt was die
Amis von der Nachricht halten. In Deutschland sind jedenfalls
erste Käufe zu sehen.
dakinky
Überlaufen bringt.
Nanotechnologie kristallisiert sich immer mehr als der nächste
Trend nach/mit Biotechnologie heraus. Bin gespannt was die
Amis von der Nachricht halten. In Deutschland sind jedenfalls
erste Käufe zu sehen.
dakinky
Da anscheinend größeres Interesse an Nanogen besteht
hier mal das Profil der Firma:
Sorce: http://www.nanogen.com
Nanogen at a Glance
Formed in 1993, Nanogen has developed technology that integrates advanced microelectronics and molecular biology on proprietary semiconductor microchips. The technology has broad commercial applications in biomedical research, medical diagnostics, genomics research, genetic testing and drug discovery. It also is potentially applicable to environmental, industrial and agricultural analyses. Nanogen`s technology uses active microelectronics to move and concentrate charged molecules to designated test sites on the semiconductor microchip. The ability to concentrate and move molecules electronically provides unique advantages of flexibility, speed, accuracy and efficiency, including:
* Significant acceleration of molecular binding greatly speeding reaction times.
* Multiplexing, or simultaneous analysis of multiple test results from a single sample.
* Open architecture design allowing microchip arrays to be customized easily and quickly by end-users, providing enhanced flexibility.
* Cost effectiveness from high volume, affordable, customizable microchip design.
* High accuracy from the ability to precisely manipulate molecules electronically and to perform automatic stringency quality checks.
* Wide applicability to charged molecules.
Nanogen`s semiconductor technology has been developed as a versatile integrated, automated system. The Company believes initial applications focusing on molecular identification and analysis will accelerate development of products that capitalize on the increasing availability of genetic information and its potential to transform human healthcare. The Company believes the planned initial use of the Nanogen system in leading research institutions will enable top researchers to apply the technology to current tasks such as DNA analysis. In addition, the open architecture design will enable researchers to develop additional novel applications. Nanogen is also pursuing collaborations with corporate partners to develop its technology for a number of applications, allowing the Company to accelerate commercialization with leading industry players while retaining opportunities to independently pursue applications outside the scope of these agreements. Strategic collaborations with Becton Dickinson for infectious disease diagnosis, Èlan for genomics analyses and Hoechst AG (through a subsidiary) for drug discovery are already underway.
Nanogen Strategy
Nanogen`s objective is to develop commercial applications for its proprietary platform technology and to promote its technology as the standard for molecular identification and analysis. Key elements of the Company`s strategy include:
Developing Research and Genomics Applications.Nanogen intends to pursue the research and genomics markets by taking advantage of the open architecture design of its technology that allows end users to customize microchips to meet their individual research needs. Nanogen believes that this build-your-own-chip capability will fulfill an unmet need for a powerful, versatile and relatively inexpensive analytical tool. Nanogen further believes that it has developed a powerful tool which will enable users to develop unforeseen and commercially attractive applications.
Developing Commercial Applications. Nanogen intends initially to develop commercial applications for its platform technology in the infectious disease diagnostic market through its joint venture with Becton Dickinson by exploiting the increasing availability of genetic information and its relationship to human disease. Nanogen also intends to leverage its technology in the rapidly developing genetic testing, drug discovery, and pharmacogenetics markets. The Company intends to build a recurring stream of revenue from the sale of low cost, disposable cartridges. Nanogen believes that widespread market penetration of its instruments and the open architecture of its systems will promote sustained demand for its disposable cartridges. In addition, Nanogen`s semiconductor microchip manufacturing will be scalable, allowing for the production of substantial volumes of disposable cartridges at a low cost. Other areas such as forensics and prenatal genetics also offer opportunities for Nanogen`s technology.
Establishing Strategic Collaborations. Nanogen intends to continue to enter into collaborations to expand applications of its technology platform and to accelerate the commercialization of products. By partnering with multinational healthcare companies, Nanogen believes that it can gain broader access to global markets, without shifting its resources from the further development of its platform technology. In addition, as part of these arrangements, Nanogen believes it can better focus on introducing its technology into expanding markets while its collaborative partners contribute their technology and expertise in areas such as sales, marketing and regulatory approvals. Nanogen will pursue additional collaborations in various forms, including research and development agreements, licensing agreements and joint ventures. These collaborations permit integration of the technology and resources of its partners with the Company`s technology, while allowing Nanogen to pursue diagnostics, drug discovery and genomics opportunities outside the scope of these collaborations.
Developing Advanced Technologies and Point-of-Care Applications. In the long term, Nanogen plans to develop sample-to-answer systems which integrate otherwise time-consuming and labor-intensive sample preparation procedures on the disposable cartridge through the use of active microelectronics. The availability of this lab-on-a-chip technology would fulfill a substantial unmet need in both academic research and commercial sectors.
hier mal das Profil der Firma:
Sorce: http://www.nanogen.com
Nanogen at a Glance
Formed in 1993, Nanogen has developed technology that integrates advanced microelectronics and molecular biology on proprietary semiconductor microchips. The technology has broad commercial applications in biomedical research, medical diagnostics, genomics research, genetic testing and drug discovery. It also is potentially applicable to environmental, industrial and agricultural analyses. Nanogen`s technology uses active microelectronics to move and concentrate charged molecules to designated test sites on the semiconductor microchip. The ability to concentrate and move molecules electronically provides unique advantages of flexibility, speed, accuracy and efficiency, including:
* Significant acceleration of molecular binding greatly speeding reaction times.
* Multiplexing, or simultaneous analysis of multiple test results from a single sample.
* Open architecture design allowing microchip arrays to be customized easily and quickly by end-users, providing enhanced flexibility.
* Cost effectiveness from high volume, affordable, customizable microchip design.
* High accuracy from the ability to precisely manipulate molecules electronically and to perform automatic stringency quality checks.
* Wide applicability to charged molecules.
Nanogen`s semiconductor technology has been developed as a versatile integrated, automated system. The Company believes initial applications focusing on molecular identification and analysis will accelerate development of products that capitalize on the increasing availability of genetic information and its potential to transform human healthcare. The Company believes the planned initial use of the Nanogen system in leading research institutions will enable top researchers to apply the technology to current tasks such as DNA analysis. In addition, the open architecture design will enable researchers to develop additional novel applications. Nanogen is also pursuing collaborations with corporate partners to develop its technology for a number of applications, allowing the Company to accelerate commercialization with leading industry players while retaining opportunities to independently pursue applications outside the scope of these agreements. Strategic collaborations with Becton Dickinson for infectious disease diagnosis, Èlan for genomics analyses and Hoechst AG (through a subsidiary) for drug discovery are already underway.
Nanogen Strategy
Nanogen`s objective is to develop commercial applications for its proprietary platform technology and to promote its technology as the standard for molecular identification and analysis. Key elements of the Company`s strategy include:
Developing Research and Genomics Applications.Nanogen intends to pursue the research and genomics markets by taking advantage of the open architecture design of its technology that allows end users to customize microchips to meet their individual research needs. Nanogen believes that this build-your-own-chip capability will fulfill an unmet need for a powerful, versatile and relatively inexpensive analytical tool. Nanogen further believes that it has developed a powerful tool which will enable users to develop unforeseen and commercially attractive applications.
Developing Commercial Applications. Nanogen intends initially to develop commercial applications for its platform technology in the infectious disease diagnostic market through its joint venture with Becton Dickinson by exploiting the increasing availability of genetic information and its relationship to human disease. Nanogen also intends to leverage its technology in the rapidly developing genetic testing, drug discovery, and pharmacogenetics markets. The Company intends to build a recurring stream of revenue from the sale of low cost, disposable cartridges. Nanogen believes that widespread market penetration of its instruments and the open architecture of its systems will promote sustained demand for its disposable cartridges. In addition, Nanogen`s semiconductor microchip manufacturing will be scalable, allowing for the production of substantial volumes of disposable cartridges at a low cost. Other areas such as forensics and prenatal genetics also offer opportunities for Nanogen`s technology.
Establishing Strategic Collaborations. Nanogen intends to continue to enter into collaborations to expand applications of its technology platform and to accelerate the commercialization of products. By partnering with multinational healthcare companies, Nanogen believes that it can gain broader access to global markets, without shifting its resources from the further development of its platform technology. In addition, as part of these arrangements, Nanogen believes it can better focus on introducing its technology into expanding markets while its collaborative partners contribute their technology and expertise in areas such as sales, marketing and regulatory approvals. Nanogen will pursue additional collaborations in various forms, including research and development agreements, licensing agreements and joint ventures. These collaborations permit integration of the technology and resources of its partners with the Company`s technology, while allowing Nanogen to pursue diagnostics, drug discovery and genomics opportunities outside the scope of these collaborations.
Developing Advanced Technologies and Point-of-Care Applications. In the long term, Nanogen plans to develop sample-to-answer systems which integrate otherwise time-consuming and labor-intensive sample preparation procedures on the disposable cartridge through the use of active microelectronics. The availability of this lab-on-a-chip technology would fulfill a substantial unmet need in both academic research and commercial sectors.
Technology
Nanogen`s proprietary platform technology takes advantage of the fact that most biological molecules are either positively or negatively charged and is ideally suited to unravelling complex genetic information. Through the use of microelectronics, Nanogen`s technology enables the active movement and concentration of charged molecules to and from designated test sites on its semiconductor microchip. The test sites may be arranged in a variety of configuration, or arrays, on the microchip. In addition, Nanogen`s technology allows for the simultaneous analysis of multiple test results, or "multiplexing," from a single sample.
Nanogen`s proprietary technology has broad applications for the analysis of unknown charged biological molecules that are capable of binding specifically to a known capture molecule on a microchip. The Company has initially focused on DNA-based sample analysis.
The Company`s technology allows small sequences of DNA capture probes to be electronically placed at, or "addressed" to, specific sites on the microchip. A test sample can then be analyzed for the presence of target DNA molecules by determining which of the DNA capture probes on the array bind, or hybridize, with complementary DNA in the test sample. In contrast to nonelectronic or passive hybridization with conventional arrays on paper or glass "chips," the use of electronically mediated active hybridization to move and concentrate target DNA molecules accelerates hybridization so that hybridization may occur in minutes rather than the hours required for passive hybridization techniques. In addition to DNA applications, Nanogen believes its technology can be applied to a number of other analyses, including antigen-antibody, enzyme-substrate, cell-receptor and cell separation techniques.
Proprietary Technology and Patents
The Company has four issued U.S. patents, one foreign issued patent, five indications of allowability and 15 additional patent application families pending in the United States. Corresponding foreign patent applications have been filed in a number of countries. See Press Releases and Publications section for more details.
Products
Through the use of microelectronics, Nanogen`s technology enables the active movement and concentration of electronically charged molecules to and from designated test sites on its semiconductor microchip. These test sites are arranged in an array on Nanogen`s microchip. In addition, its technology allows for the simultaneous analysis of multiple test results, or "multiplexing," from a single sample.
Nanogen`s proprietary technology is broadly applicable to the analysis of unknown charged biological molecules which are capable of binding specifically to known capture molecules on a microchip. The Company`s initial focus will be on DNA-based sample analysis.
Nanogen System Components
The Nanogen system consists of both a disposable cartridge containing a proprietary semiconductor microchip and a fully automated instrument that controls all aspects of microchip operations, processing, detection and reporting. The system has been designed so that the operator simply inserts a disposable cartridge containing a test sample into the instrument. All subsequent steps are handled automatically within minutes.
genauere Erklärung der Produkte: http://www.nanogen.com/www1/tech.htm
Nanogen`s proprietary platform technology takes advantage of the fact that most biological molecules are either positively or negatively charged and is ideally suited to unravelling complex genetic information. Through the use of microelectronics, Nanogen`s technology enables the active movement and concentration of charged molecules to and from designated test sites on its semiconductor microchip. The test sites may be arranged in a variety of configuration, or arrays, on the microchip. In addition, Nanogen`s technology allows for the simultaneous analysis of multiple test results, or "multiplexing," from a single sample.
Nanogen`s proprietary technology has broad applications for the analysis of unknown charged biological molecules that are capable of binding specifically to a known capture molecule on a microchip. The Company has initially focused on DNA-based sample analysis.
The Company`s technology allows small sequences of DNA capture probes to be electronically placed at, or "addressed" to, specific sites on the microchip. A test sample can then be analyzed for the presence of target DNA molecules by determining which of the DNA capture probes on the array bind, or hybridize, with complementary DNA in the test sample. In contrast to nonelectronic or passive hybridization with conventional arrays on paper or glass "chips," the use of electronically mediated active hybridization to move and concentrate target DNA molecules accelerates hybridization so that hybridization may occur in minutes rather than the hours required for passive hybridization techniques. In addition to DNA applications, Nanogen believes its technology can be applied to a number of other analyses, including antigen-antibody, enzyme-substrate, cell-receptor and cell separation techniques.
Proprietary Technology and Patents
The Company has four issued U.S. patents, one foreign issued patent, five indications of allowability and 15 additional patent application families pending in the United States. Corresponding foreign patent applications have been filed in a number of countries. See Press Releases and Publications section for more details.
Products
Through the use of microelectronics, Nanogen`s technology enables the active movement and concentration of electronically charged molecules to and from designated test sites on its semiconductor microchip. These test sites are arranged in an array on Nanogen`s microchip. In addition, its technology allows for the simultaneous analysis of multiple test results, or "multiplexing," from a single sample.
Nanogen`s proprietary technology is broadly applicable to the analysis of unknown charged biological molecules which are capable of binding specifically to known capture molecules on a microchip. The Company`s initial focus will be on DNA-based sample analysis.
Nanogen System Components
The Nanogen system consists of both a disposable cartridge containing a proprietary semiconductor microchip and a fully automated instrument that controls all aspects of microchip operations, processing, detection and reporting. The system has been designed so that the operator simply inserts a disposable cartridge containing a test sample into the instrument. All subsequent steps are handled automatically within minutes.
genauere Erklärung der Produkte: http://www.nanogen.com/www1/tech.htm
Trading Spotlight
Und das schönste an den guten News:
Sie sind gestern erst kurz vor Börsenschluss rausgekommen,
die meisten Amis stehen nun in den Startlöchern und werden heute Mittag ab 15:30 h (d.h. 9:30 in USA) an der Nasdaqu kaufen kaufen kaufen, während wir hier in aller Ruhe noch fast zum Schlusskurs des vorherigen Tages einkaufen können, denn der echte Run der wird heute mittag von den Amis losgetreten. Z.Zt. 19EUR, das sind nur 50 Cent über dem rechnerischen Eur-Wert des NGEN $-Kurses von gestern, 22:00h MEZ.
Ist ein Super-Eistieg, wenn man ne Aktie erwischt mit einem wahnsinns-Zukunftspotential und kann sofort ein paar Stunden nach dem Kauf den ersten Anstieg miterleben. Ich bin dabei Leute!
P.S: Ausserdem empfehle ich Euch TLMD www.telemonde.com
Gruss
Sie sind gestern erst kurz vor Börsenschluss rausgekommen,
die meisten Amis stehen nun in den Startlöchern und werden heute Mittag ab 15:30 h (d.h. 9:30 in USA) an der Nasdaqu kaufen kaufen kaufen, während wir hier in aller Ruhe noch fast zum Schlusskurs des vorherigen Tages einkaufen können, denn der echte Run der wird heute mittag von den Amis losgetreten. Z.Zt. 19EUR, das sind nur 50 Cent über dem rechnerischen Eur-Wert des NGEN $-Kurses von gestern, 22:00h MEZ.
Ist ein Super-Eistieg, wenn man ne Aktie erwischt mit einem wahnsinns-Zukunftspotential und kann sofort ein paar Stunden nach dem Kauf den ersten Anstieg miterleben. Ich bin dabei Leute!
P.S: Ausserdem empfehle ich Euch TLMD www.telemonde.com
Gruss
So wie es jetzt aussieht, finden die Amis die Nachricht nicht so besonders.Egal!Schaun wir mal, was die nächste Woche so bringt.
Alles Pustekuchen ..Der Abwärtstrend bei Nanogen setzt sich weiter fort..
Es gibt viele positive Nachrichten von Nanogen:
Die Vermarktung des NanoChip-Systems läuft gut an.
Problem: Der Rechtsstreit mit Motorola ...
Die Ergebnisse sind offenbar nicht schlecht.
Nanogen-Präsident Kieran Gallahue präsentiert die Q3-Zahlen am Dienstag (31.10).
Wenn dann auch das Nasdaq-Umfeld stimmt ...
trendwatcher
Die Vermarktung des NanoChip-Systems läuft gut an.
Problem: Der Rechtsstreit mit Motorola ...
Die Ergebnisse sind offenbar nicht schlecht.
Nanogen-Präsident Kieran Gallahue präsentiert die Q3-Zahlen am Dienstag (31.10).
Wenn dann auch das Nasdaq-Umfeld stimmt ...
trendwatcher
Monday October 30, 11:21 am Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Hitachi Ships Nanogen System to Children`s Hospital of Tokyo
SAN DIEGO, Oct. 30 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today the shipment of a NanoChip(TM) instrument system to National Children`s Hospital of Tokyo by Nissei Sangyo Inc., a distribution company of Hitachi, Ltd.
National Children`s Hospital represents the first customer to be served under Nanogen and Hitachi`s distribution agreement for Japan. The NanoChip system is intended for use in the development of clinically relevant single nucleotide polymorphism (SNP) based tests for diagnosing and determining appropriate treatment for childhood asthma/allergy patients.
Howard Birndorf, Nanogen`s Chairman and CEO, commented, ``We are quite pleased to have begun serving the Japanese market with our partner Nissei Sangyo. National Children`s Hospital represents an important step by Nissei Sangyo in their process of methodically building a presence in the attractive Japanese clinical research market. The National Children`s Hospital shipment also demonstrates that the clinical research market is a worldwide opportunity, as researchers in various geographic regions seek to accelerate the introduction of clinically relevant tests into the patient care process.``
Hitachi, Ltd., headquartered in Tokyo, Japan, is one of the world`s leading global electronics companies, with fiscal 1999 (ended March 31, 2000) consolidated sales of 8,001 billion yen ($75.5 billion*). The company manufactures and markets a wide range of products, including computers, semiconductors, consumer products and power and industrial equipment. Scientific instrumentation is developed and manufactured through its Instrument Group based in Tokyo, Japan with a principle factory in Hitachinaka City. Hitachi has been a leading supplier of instrumentation for research applications in highly regulated markets such as clinical diagnostics and medical instrumentation. For more information on Hitachi, Ltd., please visit the Hitachi Web site at http://www.hitachi.co.jp.
* (At an exchange rate of 106 yen to the dollar.)
Nissei Sangyo Co. Ltd., headquartered in Tokyo, Japan was established in 1947 as a trading company within Hitachi Group. Nissei covers extensive business areas from Electronics and Informatics to Scientific Instruments. In fiscal 1999 (ended March 31, 2000), Nissei had consolidated sales of over 725 billion yen ($6.8 billion). Nissei is the exclusive sales representative for Hitachi scientific instruments worldwide. For more information concerning Nissei Sangyo Co., Ltd., please visit Hitachi`s Internet web site at: http://www.Nisseisg.co.jp.
Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation and its NanoChip(TM) Cartridge to scientists and genomics laboratories, setting new standards for SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genetic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, ``bridging`` the research and clinical diagnostic settings. For information on purchasing the NanoChip(TM) System in the U.S., please call 1-877-Nanogen or visit prodinfo@nanogen.com and in Europe, please call Peter Halkjaer-Knudsen, European Marketing Manager at 011-45-45-767202 or visit phk@nanogen.com. For additional product and company information, please visit Nanogen`s web site at http://www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by the Company`s customers or partners can be replicated, whether the Company`s products will be purchased by other customers and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Contact: Kieran T. Gallahue Page Sargisson, ext. 229
President/CFO Media
Nanogen, Inc. Noonan/Russo Communications
(858) 410-4600 (415) 677-4455
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Hitachi Ships Nanogen System to Children`s Hospital of Tokyo
SAN DIEGO, Oct. 30 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today the shipment of a NanoChip(TM) instrument system to National Children`s Hospital of Tokyo by Nissei Sangyo Inc., a distribution company of Hitachi, Ltd.
National Children`s Hospital represents the first customer to be served under Nanogen and Hitachi`s distribution agreement for Japan. The NanoChip system is intended for use in the development of clinically relevant single nucleotide polymorphism (SNP) based tests for diagnosing and determining appropriate treatment for childhood asthma/allergy patients.
Howard Birndorf, Nanogen`s Chairman and CEO, commented, ``We are quite pleased to have begun serving the Japanese market with our partner Nissei Sangyo. National Children`s Hospital represents an important step by Nissei Sangyo in their process of methodically building a presence in the attractive Japanese clinical research market. The National Children`s Hospital shipment also demonstrates that the clinical research market is a worldwide opportunity, as researchers in various geographic regions seek to accelerate the introduction of clinically relevant tests into the patient care process.``
Hitachi, Ltd., headquartered in Tokyo, Japan, is one of the world`s leading global electronics companies, with fiscal 1999 (ended March 31, 2000) consolidated sales of 8,001 billion yen ($75.5 billion*). The company manufactures and markets a wide range of products, including computers, semiconductors, consumer products and power and industrial equipment. Scientific instrumentation is developed and manufactured through its Instrument Group based in Tokyo, Japan with a principle factory in Hitachinaka City. Hitachi has been a leading supplier of instrumentation for research applications in highly regulated markets such as clinical diagnostics and medical instrumentation. For more information on Hitachi, Ltd., please visit the Hitachi Web site at http://www.hitachi.co.jp.
* (At an exchange rate of 106 yen to the dollar.)
Nissei Sangyo Co. Ltd., headquartered in Tokyo, Japan was established in 1947 as a trading company within Hitachi Group. Nissei covers extensive business areas from Electronics and Informatics to Scientific Instruments. In fiscal 1999 (ended March 31, 2000), Nissei had consolidated sales of over 725 billion yen ($6.8 billion). Nissei is the exclusive sales representative for Hitachi scientific instruments worldwide. For more information concerning Nissei Sangyo Co., Ltd., please visit Hitachi`s Internet web site at: http://www.Nisseisg.co.jp.
Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation and its NanoChip(TM) Cartridge to scientists and genomics laboratories, setting new standards for SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genetic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, ``bridging`` the research and clinical diagnostic settings. For information on purchasing the NanoChip(TM) System in the U.S., please call 1-877-Nanogen or visit prodinfo@nanogen.com and in Europe, please call Peter Halkjaer-Knudsen, European Marketing Manager at 011-45-45-767202 or visit phk@nanogen.com. For additional product and company information, please visit Nanogen`s web site at http://www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by the Company`s customers or partners can be replicated, whether the Company`s products will be purchased by other customers and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Contact: Kieran T. Gallahue Page Sargisson, ext. 229
President/CFO Media
Nanogen, Inc. Noonan/Russo Communications
(858) 410-4600 (415) 677-4455
SOURCE: Nanogen, Inc.
Übrigens:
Morgen Quartalszahlen bei Nanogen.
Morgen Quartalszahlen bei Nanogen.
und hier die nächste meldung
Tuesday October 31, 7:30 am Eastern Time
Press Release
SOURCE: Nanogen, Inc. and The Children`s Hospital of Philadelphia
Nanogen and The Children`s Hospital of Philadelphia Sign Collaboration
Agreement
- Focus on Development of High-Accuracy Genetic Tests -
SAN DIEGO, and PHILADELPHIA, Oct. 31 /PRNewswire/ -- Nanogen, Inc., (Nasdaq: NGEN - news) and The Children`s Hospital of Philadelphia announced
today that they will collaborate to develop high-accuracy genetic tests on Nanogen`s platform.
Paolo Fortina, M.D., Ph.D., an investigator at the Joseph Stokes, Jr. Research Institute of The Children`s Hospital of Philadelphia, recently presented successful
preliminary results from difficult genetic samples run on Nanogen`s system at the International Forum of Biochip Technologies in Beijing. The samples included DNA
insertions and deletions.
The Children`s Hospital of Philadelphia is considered a world leader in caring for children with diseases caused by a deletion of DNA on chromosome 22.
Chromosome 22q11.2 deletion syndrome is characterized by cardiac defects, cleft palate and feeding problems, among other things. Because physicians at
Children`s Hospital care for hundreds of children with this and other genetic diseases, access to fast and accurate genetic tests is an important component of the
Hospital`s clinical and research programs.
The object of the Nanogen/Children`s Hospital collaboration is to accelerate development of clinical diagnostics assays on Nanogen`s unique DNA microchips,
potentially leading toward higher quality, more timely diagnostic results. This is the first collaboration announced under Nanogen`s Development Site Program. Under
the agreement, Children`s Hospital will provide laboratory resources, collaborative expertise and product revenue in exchange for non-exclusive access to Nanogen`s
electronic DNA microarray technology. Nanogen and Children`s Hospital have also agreed to publish and present the validated study results. Children`s Hospital
intends to develop genetic tests using Nanogen`s NanoChip(TM) platform for use in the hospital`s clinical laboratories.
``I have been utilizing microarray technologies for several years,`` said Dr. Fortina, of the Hematology Division at Children`s Hospital and an associate professor of
Pediatrics at the University of Pennsylvania School of Medicine. ``When evaluating the NanoChip(TM) technology, Nanogen asked for us to submit our most
difficult samples to run as a performance demonstration. We gave them several different types, including Factor VII exon 8 amino acid 353, a decanucleotide
insertion/deletion at position *323 in the Factor VII promoter, MTHFR and Protein C SNP 1, 2 and 3. All samples were reported unambiguously and 100 percent
correct.`` Dr. Fortina concluded, ``We believe this technology will allow us to develop a variety of highly accurate genetic tests for the benefit of the healthcare
community.``
Howard Birndorf, Chairman and Chief Executive Officer of Nanogen commented: ``The Children`s Hospital of Pennsylvania has clearly demonstrated a desire to
improve patient care through the use of genetically-based diagnostic assays. We are pleased that they view the NanoChip(TM) technology as a key enabling
technology that may reduce the time-to-market and accuracy of a broad selection of reliable genetic tests. The objective of our relationship with the Children`s
Hospital is to develop new diagnostic tests that will assist medical doctors in the treatment of childhood diseases. The agreement with Children`s Hospital broadens
our development efforts by applying the NanoChip(TM) technology to the most challenging areas of genetic testing, clearly differentiating our product from other
systems.``
Microarray Technologies: New Tools for the Genomics and Post-Genomics Revolution
Human genomics, the study of the location and function of the tens of thousands of genes in every human cell, is increasingly the focus of medical and pharmaceutical
research. Understanding and decoding genomes is expected to accelerate the development of diagnostic procedures and of new drugs to detect, prevent and cure
disease.
Genomics is not limited to the study of human genomes. Other genomes, such as bacterial, viral, animal and plant genomes, hold commercial implications. As the
DNA sequencing of genomes are completed and more genes are functionally linked to biological processes or diseases, the tools used in laboratories must be
replaced or adapted to the very different standards required for post-genomics work. For example, while the priority in discovery genomics is very high throughput,
in post-genomics applications, such as certain DNA diagnostic assays, the priority is accuracy and versatility.
Nanogen and its customers have found the NanoChip(TM) system produces industry-leading accuracy for scoring genetic variations in patients, including single
nucleotide polymorphisms (SNPs), insertions, deletions and repeats. The no call rate on NanoChip(TM) systems has also been very low. Other techniques permit
high or very high throughput of either samples or SNPs, but most of these techniques do not work well with the other types of genetic variants. To date, the most
difficult samples, such as microvariants (or mutations within DNA repeat sequences), mutations that are adjacent to secondary DNA structures, repeat regions,
insertions, deletions, and scoring SNPs in genes found to have pseudogenes have been successfully analyzed on the NanoChip(TM) Molecular Biology Workstation
and its multi-use consumable, the NanoChip(TM) cartridge.
Under development at Nanogen are additional applications on the NanoChip(TM) platform, including high precision gene expression monitoring from multiple
experiments on the same NanoChip(TM). Gene expression currently is used primarily in research and in the near future is expected to be used routinely in clinical
diagnostics if a more reproducible system becomes available.
Nanogen`s Development Site Program
Nanogen has established the Development Site Program to actively collaborate with selected customers in strategically important market segments (including clinical
research, reference diagnostic laboratories, genomics, pharmaceutical, biotechnology and agrochemical companies) in the development of assays on the Nanogen
platform. Under these agreements, collaborating companies and institutions provide expertise and/or intellectual property in exchange for early access to Nanogen`s
technology. After applications are validated, the collaborating institutions may purchase the NanoChip(TM) Workstation and NanoChip(TM) cartridges for use in
their operations.
The Children`s Hospital of Philadelphia
Founded in 1855 as the nation`s first pediatric medical center, The Children`s Hospital of Philadelphia is a leader in patient care, education and research. The
Hospital is second in the United States among all children`s hospitals in total research funding from the National Institutes of Health.
Basic research in human genetics and clinical programs for children with genetic disease are major strengths at Children`s Hospital. Investigators from the Hospital,
led by Beverly S. Emanuel, Ph.D., chief of the division of Human Genetics and Molecular Biology, played an important role in the milestone announced last year by
the Human Genome Project, that chromosome 22 was the first human chromosome to be sequenced. Dr. Emanuel`s team also has analyzed areas of genetic
instability occurring in chromosome 22q11 deletion syndrome. Understanding the molecular mechanisms behind low-copy repeats will be important in an emerging
field of medicine called genomic disease-conditions that originate in the structure of the genome.
Dr. Paolo Fortina is a pediatrician and Director of the clinical Molecular Pathology section at Children`s Hospital. Dr. Fortina has an interest in developing
microdevice-based approaches for sample preparation, gene expression profiling and the detection of genetic mutations. In collaboration with the Department of
Pathology and Laboratory Medicine at The Hospital of the University of Pennsylvania, his group is developing a fully-integrated microdevice which will begin with a
drop of blood and end with a genetic profile of the individual. The device is intended to improve genetic testing while saving time and decreasing the costs of analysis.
Dr. Fortina`s current work is aimed at implementing protocols employing microarrays in diagnostics for common inheritable genetic diseases. He also is collaborating
in international studies aimed at discovering genes that regulate the switch from fetal to adult hemoglobin production as well as genes involved in inflammatory bowel
disease. In another project, Dr. Fortina and Dr. Eleanor Pollak, a pathologist at the University of Pennsylvania, are studying the potential use of a microdevice to
study genetic risk factors for pathological blood clotting associated with cardiovascular disease.
Nanogen, Inc.
Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for
SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical
understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA
and proteins, ``bridging`` both the research and clinical diagnostic settings. For additional information please visit Nanogen`s web site at http://www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set
forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be or will be further successfully commercialized, whether
products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated,
whether the Company`s collaborations will continue to be funded and other risks and uncertainties discussed under the caption ``Factors That May Affect Results``
and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999, as amended, and subsequent reports filed with the Securities
and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these
forward-looking statements. The Company may, at its discretion, issue additional announcements regarding orders or sales of it NanoChip(TM) system as it deems
appropriate and as required by law.
Contact: Kieran T. Gallahue, President, CFO, of Nanogen, Inc., 858-410-4600; or Page Sargisson, Media, of Noonan-Russo Communications, 415-677-4455,
ext. 229, for Nanogen, Inc.
SOURCE: Nanogen, Inc. and The Children`s Hospital of Philadelphia
sollte also bald aufwärts gehen bei ansprechenden zahlen heute
allerdings erst nach boerseschluss werden -0,34 cents erwrtet laut yahoo
Tuesday October 31, 7:30 am Eastern Time
Press Release
SOURCE: Nanogen, Inc. and The Children`s Hospital of Philadelphia
Nanogen and The Children`s Hospital of Philadelphia Sign Collaboration
Agreement
- Focus on Development of High-Accuracy Genetic Tests -
SAN DIEGO, and PHILADELPHIA, Oct. 31 /PRNewswire/ -- Nanogen, Inc., (Nasdaq: NGEN - news) and The Children`s Hospital of Philadelphia announced
today that they will collaborate to develop high-accuracy genetic tests on Nanogen`s platform.
Paolo Fortina, M.D., Ph.D., an investigator at the Joseph Stokes, Jr. Research Institute of The Children`s Hospital of Philadelphia, recently presented successful
preliminary results from difficult genetic samples run on Nanogen`s system at the International Forum of Biochip Technologies in Beijing. The samples included DNA
insertions and deletions.
The Children`s Hospital of Philadelphia is considered a world leader in caring for children with diseases caused by a deletion of DNA on chromosome 22.
Chromosome 22q11.2 deletion syndrome is characterized by cardiac defects, cleft palate and feeding problems, among other things. Because physicians at
Children`s Hospital care for hundreds of children with this and other genetic diseases, access to fast and accurate genetic tests is an important component of the
Hospital`s clinical and research programs.
The object of the Nanogen/Children`s Hospital collaboration is to accelerate development of clinical diagnostics assays on Nanogen`s unique DNA microchips,
potentially leading toward higher quality, more timely diagnostic results. This is the first collaboration announced under Nanogen`s Development Site Program. Under
the agreement, Children`s Hospital will provide laboratory resources, collaborative expertise and product revenue in exchange for non-exclusive access to Nanogen`s
electronic DNA microarray technology. Nanogen and Children`s Hospital have also agreed to publish and present the validated study results. Children`s Hospital
intends to develop genetic tests using Nanogen`s NanoChip(TM) platform for use in the hospital`s clinical laboratories.
``I have been utilizing microarray technologies for several years,`` said Dr. Fortina, of the Hematology Division at Children`s Hospital and an associate professor of
Pediatrics at the University of Pennsylvania School of Medicine. ``When evaluating the NanoChip(TM) technology, Nanogen asked for us to submit our most
difficult samples to run as a performance demonstration. We gave them several different types, including Factor VII exon 8 amino acid 353, a decanucleotide
insertion/deletion at position *323 in the Factor VII promoter, MTHFR and Protein C SNP 1, 2 and 3. All samples were reported unambiguously and 100 percent
correct.`` Dr. Fortina concluded, ``We believe this technology will allow us to develop a variety of highly accurate genetic tests for the benefit of the healthcare
community.``
Howard Birndorf, Chairman and Chief Executive Officer of Nanogen commented: ``The Children`s Hospital of Pennsylvania has clearly demonstrated a desire to
improve patient care through the use of genetically-based diagnostic assays. We are pleased that they view the NanoChip(TM) technology as a key enabling
technology that may reduce the time-to-market and accuracy of a broad selection of reliable genetic tests. The objective of our relationship with the Children`s
Hospital is to develop new diagnostic tests that will assist medical doctors in the treatment of childhood diseases. The agreement with Children`s Hospital broadens
our development efforts by applying the NanoChip(TM) technology to the most challenging areas of genetic testing, clearly differentiating our product from other
systems.``
Microarray Technologies: New Tools for the Genomics and Post-Genomics Revolution
Human genomics, the study of the location and function of the tens of thousands of genes in every human cell, is increasingly the focus of medical and pharmaceutical
research. Understanding and decoding genomes is expected to accelerate the development of diagnostic procedures and of new drugs to detect, prevent and cure
disease.
Genomics is not limited to the study of human genomes. Other genomes, such as bacterial, viral, animal and plant genomes, hold commercial implications. As the
DNA sequencing of genomes are completed and more genes are functionally linked to biological processes or diseases, the tools used in laboratories must be
replaced or adapted to the very different standards required for post-genomics work. For example, while the priority in discovery genomics is very high throughput,
in post-genomics applications, such as certain DNA diagnostic assays, the priority is accuracy and versatility.
Nanogen and its customers have found the NanoChip(TM) system produces industry-leading accuracy for scoring genetic variations in patients, including single
nucleotide polymorphisms (SNPs), insertions, deletions and repeats. The no call rate on NanoChip(TM) systems has also been very low. Other techniques permit
high or very high throughput of either samples or SNPs, but most of these techniques do not work well with the other types of genetic variants. To date, the most
difficult samples, such as microvariants (or mutations within DNA repeat sequences), mutations that are adjacent to secondary DNA structures, repeat regions,
insertions, deletions, and scoring SNPs in genes found to have pseudogenes have been successfully analyzed on the NanoChip(TM) Molecular Biology Workstation
and its multi-use consumable, the NanoChip(TM) cartridge.
Under development at Nanogen are additional applications on the NanoChip(TM) platform, including high precision gene expression monitoring from multiple
experiments on the same NanoChip(TM). Gene expression currently is used primarily in research and in the near future is expected to be used routinely in clinical
diagnostics if a more reproducible system becomes available.
Nanogen`s Development Site Program
Nanogen has established the Development Site Program to actively collaborate with selected customers in strategically important market segments (including clinical
research, reference diagnostic laboratories, genomics, pharmaceutical, biotechnology and agrochemical companies) in the development of assays on the Nanogen
platform. Under these agreements, collaborating companies and institutions provide expertise and/or intellectual property in exchange for early access to Nanogen`s
technology. After applications are validated, the collaborating institutions may purchase the NanoChip(TM) Workstation and NanoChip(TM) cartridges for use in
their operations.
The Children`s Hospital of Philadelphia
Founded in 1855 as the nation`s first pediatric medical center, The Children`s Hospital of Philadelphia is a leader in patient care, education and research. The
Hospital is second in the United States among all children`s hospitals in total research funding from the National Institutes of Health.
Basic research in human genetics and clinical programs for children with genetic disease are major strengths at Children`s Hospital. Investigators from the Hospital,
led by Beverly S. Emanuel, Ph.D., chief of the division of Human Genetics and Molecular Biology, played an important role in the milestone announced last year by
the Human Genome Project, that chromosome 22 was the first human chromosome to be sequenced. Dr. Emanuel`s team also has analyzed areas of genetic
instability occurring in chromosome 22q11 deletion syndrome. Understanding the molecular mechanisms behind low-copy repeats will be important in an emerging
field of medicine called genomic disease-conditions that originate in the structure of the genome.
Dr. Paolo Fortina is a pediatrician and Director of the clinical Molecular Pathology section at Children`s Hospital. Dr. Fortina has an interest in developing
microdevice-based approaches for sample preparation, gene expression profiling and the detection of genetic mutations. In collaboration with the Department of
Pathology and Laboratory Medicine at The Hospital of the University of Pennsylvania, his group is developing a fully-integrated microdevice which will begin with a
drop of blood and end with a genetic profile of the individual. The device is intended to improve genetic testing while saving time and decreasing the costs of analysis.
Dr. Fortina`s current work is aimed at implementing protocols employing microarrays in diagnostics for common inheritable genetic diseases. He also is collaborating
in international studies aimed at discovering genes that regulate the switch from fetal to adult hemoglobin production as well as genes involved in inflammatory bowel
disease. In another project, Dr. Fortina and Dr. Eleanor Pollak, a pathologist at the University of Pennsylvania, are studying the potential use of a microdevice to
study genetic risk factors for pathological blood clotting associated with cardiovascular disease.
Nanogen, Inc.
Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for
SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical
understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA
and proteins, ``bridging`` both the research and clinical diagnostic settings. For additional information please visit Nanogen`s web site at http://www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set
forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be or will be further successfully commercialized, whether
products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated,
whether the Company`s collaborations will continue to be funded and other risks and uncertainties discussed under the caption ``Factors That May Affect Results``
and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999, as amended, and subsequent reports filed with the Securities
and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these
forward-looking statements. The Company may, at its discretion, issue additional announcements regarding orders or sales of it NanoChip(TM) system as it deems
appropriate and as required by law.
Contact: Kieran T. Gallahue, President, CFO, of Nanogen, Inc., 858-410-4600; or Page Sargisson, Media, of Noonan-Russo Communications, 415-677-4455,
ext. 229, for Nanogen, Inc.
SOURCE: Nanogen, Inc. and The Children`s Hospital of Philadelphia
sollte also bald aufwärts gehen bei ansprechenden zahlen heute
allerdings erst nach boerseschluss werden -0,34 cents erwrtet laut yahoo
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,50 | |
| +0,74 | |
| 0,00 | |
| +1,11 | |
| +0,19 | |
| +19,13 | |
| +53,85 | |
| -0,06 | |
| 0,00 | |
| +1,62 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 90 | ||
| 78 | ||
| 58 | ||
| 55 | ||
| 35 | ||
| 34 | ||
| 29 | ||
| 26 | ||
| 25 |
